IMARC Group’s report titled “Transcriptomics Market Report by Type (Instruments, Consumables, Software, Services), Technology (Microarray, Real-Time Quantitative Polymerase Chain Reaction (Q-PCR), Sequencing Technologies), Application (Diagnostics and Disease Profiling, Drug Discovery, and Others), End User (Academic and Research Institutes, Pharmaceutical Companies, Biotechnology Companies, and Others), and Region 2025-2033”. The global transcriptomics market size reached USD 7.6 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 12.1 Billion by 2033, exhibiting a growth rate (CAGR) of 5.3% during 2025-2033.
Factors Affecting the Growth of the Transcriptomics Industry:
● Advancements in Sequencing Technologies:
Technological development in the area of sequencing is augmenting the market at the present day. New generation sequencing is progressively being adopted to sequence ribonucleic acid (RNA) sequences at high throughput and with high accuracy and speed. These technologies allow the identification of virtually all regions of the genome that are actively transcribed and consequently provide a detailed view of the functional landscape of the genome as well as a roadmap of the control mechanisms. Also, owing to the reduced costs involved in sequencing these technologies are now being adopted by more individuals and organizations. Such democratized availability drives increase in transcriptomics research across each application area including field-intensive, fundamental scientific inquiries, tests or diagnostics and even individualized medicine. Therefore, it is clear that the addition of improvements and developments of the sequencing technologies remain most prominent for enhancing the opportunities and potential of transcriptomics.
● Increasing Focus on Personalized Medicine:
A favourable market trend that is being witnessed is being eluted from the growing adoption of personalized medicine. Personalized medicine is based on the primary assessment of patients in terms of their genetic and molecular characteristics. Transcriptomics plays an important role in giving information on gene expression patterns to be used in biomarker discovery for diagnosis, disease progression and treatment response. It enables the development of optimal treatments which can minimise undesired side effects and therefore boost the complicated patients’ satisfaction and quality of life. Transcriptomics is rapidly gaining popularity among pharmaceutical companies and healthcare providers who use it to create personalized medication regimen. In addition, there is a growth in governmental and other private funding to perform the research in the personalized medicine that in turn advances the integration of the transcriptomic data into the clinical care environment.
● Rising Prevalence of Chronic Diseases and Cancer:
The rise in chronic diseases and cancer is boosting market growth. Conditions like diabetes, heart disease, and cancers challenge global healthcare. Understanding their molecular mechanisms is key for effective treatments and prevention. Transcriptomics sheds light on gene expression changes in diseases. This helps identify new treatment targets and biomarkers. The demand for better diagnostics and personalized treatments fuels the need for transcriptomic analysis.
Grab a sample PDF of this report: https://www.imarcgroup.com/transcriptomics-market/requestsample
Leading Companies Operating in the Global Transcriptomics Industry:
- Agilent Technologies Inc.
- Becton Dickinson and Company
- BGI Group
- Bio-Rad Laboratories Inc.
- Biospyder Technologies Inc.
- Illumina Inc.
- Nanostring Technologies Inc.
- Qiagen, Roche Holding AG
- Takara Bio Inc.
- Thermo Fisher Scientific Inc.
Transcriptomics Market Report Segmentation:
By Type:
- Instruments
- Consumables
- Software
- Services
Consumables represent the largest segment due to their essential and recurring use in transcriptomic experiments and analyses.
By Technology:
- Microarray
- Real-Time Quantitative Polymerase Chain Reaction (Q-PCR)
- Sequencing Technologies
Real-time quantitative polymerase chain reaction (Q-PCR) holds the biggest market share because of its widespread application in precise and quantifiable gene expression analysis.
By Application:
- Diagnostics and Disease Profiling
- Drug Discovery
- Others
Drug discovery represents the leading segment, as transcriptomics plays a critical role in identifying novel therapeutic targets and understanding disease mechanisms.
By End User:
- Academic and Research Institutes
- Pharmaceutical Companies
- Biotechnology Companies
- Others
On the basis of the end user, the market has been divided into academic and research institutes, pharmaceutical companies, biotechnology companies, and others.
Regional Insights:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
North America’s dominance in the transcriptomics market is attributed to its advanced healthcare infrastructure, substantial research funding, and the presence of leading biotech and pharmaceutical companies.
Global Transcriptomics Market Trends:
Increasing investments in genomic research are fueling market growth. Governments, private institutions, and healthcare organizations recognize the potential of genomic studies in advancing medical science and improving health outcomes. Substantial funding is being allocated to research projects that use transcriptomic technologies to explore gene expression patterns and their implications in health and disease. These investments support the development of innovative transcriptomic tools and methodologies, enhancing the ability to perform large-scale and high-resolution studies. In addition, collaborations between academic institutions and biotech companies are promoting the integration of transcriptomics into broader genomic research initiatives. This financial and collaborative support accelerates the discovery of new biomarkers, therapeutic targets, and diagnostic tools, thereby promoting innovation within the market.
Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact US
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1–631–791–1145
